BC-1215   Click here for help

GtoPdb Ligand ID: 12671

Synonyms: BC 1215 | BC1215
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: BC-1215 has been reported as an inhibitor of cytokine release that acts by targeting the ApaG motif in the C-terminal domain of ubiquitin E3 ligase F box component (Fbxo3) [2-4]. It blocks Fbxo3 interaction with the TRAF inhibitory protein Fbxl2, which results in elevation of Fbxl2-mediated degradation of TRAF proteins and ultimately decreases release of pro-inflammatory cytokines from monocytes. BC-1215 maps to compound 005 in patent US20180071232A, in which it is claimed for potential to treat inflammatory respiratory disease or injury [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 48.78
Molecular weight 394.51
XLogP 0.59
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC(=NC=C1)C2=CC=C(C=C2)CNCCNCC3=CC=C(C=C3)C4=NC=CC=C4
Isomeric SMILES C1=CC=NC(=C1)C2=CC=C(C=C2)CNCCNCC3=CC=C(C=C3)C4=CC=CC=N4
InChI InChI=1S/C26H26N4/c1-3-15-29-25(5-1)23-11-7-21(8-12-23)19-27-17-18-28-20-22-9-13-24(14-10-22)26-6-2-4-16-30-26/h1-16,27-28H,17-20H2
InChI Key IXEPQJQQSLMESJ-UHFFFAOYSA-N
Immunopharmacology Comments
An immune modulating compound that reduces cytokine release by blocking degradation of a TRAF inhibitory protein (Fbxl2); a novel approach for combating immune-related disorders, such as sepsis and colitis, which are characterised by an amplified host inflammatory response.